A study to assess anogenital lichen sclerosus et atrophicus (LSA) in a series of patients with cancer on immunotherapy
Latest Information Update: 07 Jun 2022
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Lung cancer; Malignant melanoma; Renal cancer
- Focus Adverse reactions
Most Recent Events
- 07 Jun 2022 New trial record
- 01 Jun 2022 Results published in the Cancer Immunology Immunotherapy